MarkFaberDO

PubMed

• 1 citations
  Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia.
  Hassan Awada, Mina Abdelmalek, Tara Cronin, Jeffrey Baron, Zakariya Kashour, Farhan Azad, Muhammad Salman Faisal, Mark Faber, Matthew Gravina, Pamela J Sung, Steven D ...> ;Blood Cancer Journal. 2023 Sep 4
• 7 citations
  Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy.
  Jurjen Versluis, Manu Pandey, Yael Flamand, J Erika Haydu, Roger Belizaire, Mark Faber, Rahul S Vedula, Anne Charles, Kevin M Copson, Shai Shimony, Alon Rozental, Pava...> ;Blood Advances. 2022 May 10
• 1 citations
  Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience.
  Mark G Faber, Chong Wang, Sruthi Kommi Reddy, Alison Meagher, Amy Early, Hongbin Chen, Grace K Dy> ;Lung Cancer. 2022 Mar 1
• 13 citations
  Mutant- and-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy.
  Abhay Singh, Nuria Mencia-Trinchant, Elizabeth A Griffiths, Alaa Altahan, Mahesh Swaminathan, Medhavi Gupta, Matthew Gravina, Rutaba Tajammal, Mark G Faber, LunBiao Ya...> ;JCO Precision Oncology. 2022 Jan 1
• 2 citations
  Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States.
  Abhay Singh, Megan M. Herr, Elizabeth A. Griffiths, Amanda Przespolewski, Mark G. Faber, Chebli Mrad, Eunice S. Wang, Theresa Hahn, Swapna Thota> ;Scientific Reports. 2021 Dec 2
• 2 citations
  Outcomes of Adult Acute Myeloid Leukemia Treated With Gemtuzumab-Ozogamicin: Cue To Optimized Chemotherapy Backbone
  Abhay Singh, Swapna Thota, Terrence Bradley, Elizabeth A. Griffiths, Mark G. Faber, Sarah Sadek, Amanda Przespolewski, James E. Thompson, Jeffrey Baron, Tara Cronin, K...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Sep 1
• 2 citations
  Predictors of vascular disease in myelodysplastic syndromes.
  Mark G Faber, David R Lloyd, Abhay Singh, Jeffrey Baron, Amanda Przespolewski, Elizabeth A Griffiths, Eunice S Wang, Swapna Thota> ;Ejhaem. 2020 Nov 1
• 4 citations
  Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospectiv...
  Zachary Schlei, Wei Tan, Mark G. Faber, Hongbin Chen, Alison Meagher, Grace K. Dy> ;Clinical Lung Cancer. 2018 Jun 5
• Join now to see all

Journal Articles

• Predictors of vascular disease in myelodysplastic syndromes  
  Mark G. Faber David R. Lloyd Abhay Singh Jeffrey Baron Amanda Przespolewski Elizabeth A. Griffiths Eunice S. Wang Swapna Thota, eJHaem, 9/28/2020
• Current State of Myelodysplastic Syndromes: Standard Treatment Practices and Therapeutic Advances  
  Mark G Faber, DO; Elizabeth A Griffiths, MD; Swapna Thota, MD, Journal of Clinical Pathways, 7/2019